Alterome therapeutics raises $132 million in series b financing led by goldman sachs alternatives

San diego--(business wire)--alterome therapeutics, inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million series b financing. proceeds from the fundraise will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific akt1 e17k inhibitor and a kras selective inhibitor. the financing was led by goldm.
GS Ratings Summary
GS Quant Ranking